Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 10/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2994374 | 0.99 | SMPD1 (0.45) | SMPD1BCHEACHEPTGER1PTGER4 | |
| SCHEMBL13010031 | 0.93 | PTGER1 (0.46) | SMPD1BCHEACHEPTGER1PTGER4 | |
| SCHEMBL13009987 | 0.91 | SMPD1 (0.42) | SMPD1BCHEACHECARM1PRMT1 | |
| SCHEMBL13010015 | 0.90 | PTGER1 (0.44) | SMPD1BCHEACHEPTGER1PTGER4 | |
| SCHEMBL13010004 | 0.86 | CARM1 (0.43) | BCHEACHEPTGER1PTGER4PTGER3 | |
| SCHEMBL13010011 | 0.86 | FFAR4 (0.46) | SMPD1BCHEACHEPTGER1PTGER4 | |
| SCHEMBL13010000 | 0.85 | BCHE (0.38) | BCHEACHEPTGER1PTGER4PTGER3 | |
| SCHEMBL13010007 | 0.85 | PTGER1 (0.41) | SMPD1BCHEACHEPTGER1PTGER4 | |
| SCHEMBL13207123 | 0.84 | PTGER1 (0.44) | SMPD1BCHEACHEPTGER1PTGER4 | |
| SCHEMBL13009638 | 0.84 | PTGER1 (0.44) | SMPD1BCHEACHEPTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| EP-1216225-B1 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | SMPD1 668/4885BCHE 2440/4885ACHE 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.